United States Multiomics Market Size, Share, Growth, and Industry Analysis, By Omics Type (Genomics, Transcriptomics, Proteomics, Metabolomics), By Application (Drug Discovery and Development, Precision Medicine and Personalized Therapy, Biomarker Identification, Clinical Diagnostics) and Forecast, 2026-2034

United States Multiomics Market Trends

Integration of AI, Single-Cell and Cloud-Based Biological Analysis

Multiomic research is shifting from disconnected analysis pipelines toward unified software environments combining 4 or more biological modalities. Illumina released Connected Multiomics in January 2026 after input from 40 early-access users, integrating genomics, transcriptomics, proteomics and epigenomics within a cloud-based environment. Its February 2026 v1.1 release added AI-assisted workflow suggestions, while v1.2 followed in June 2026 with expanded eQTL and pQTL workflows.

High-throughput single-cell, spatial biology and mass-spectrometry workflows are simultaneously increasing data volume and analytical complexity. A 2025 automated multiomics study evaluated 10 clinical datasets and generated 360 hypotheses, illustrating how AI-supported systems can process large heterogeneous datasets. Bruker's metabolomics expansion also includes standardized technology capable of measuring more than 1,000 metabolites across over 40 metabolite classes, strengthening integrated proteomic-metabolomic workflows.

United States Multiomics Market Drivers

Expansion of Precision Biology and High-Throughput Drug Research

Drug developers increasingly combine 3–5 molecular layers to improve target identification, patient stratification and biomarker validation. Illumina's 2025 roadmap expanded across genomics, spatial transcriptomics, single-cell analysis, CRISPR, epigenetics and multimodal analytics, while its 2026 platform incorporates at least 4 major omics classes. Bruker's metabolomics portfolio can quantify more than 1,000 metabolites across 40+ classes, demonstrating the scale of molecular information increasingly available to pharmaceutical researchers.

United States Multiomics Market Restraints

High Instrument Costs and Computational Complexity Limit Broad Deployment

Multiomics laboratories face substantial capital and informatics requirements because sequencing, mass spectrometry and spatial platforms can involve hundreds of thousands of dollars in equipment investment. Industry user discussions in 2025 cited approximately USD 750,000 budgets for high-resolution mass spectrometry systems, while multiomic datasets may integrate 4–7 molecular layers requiring extensive storage, normalization and bioinformatics expertise. These requirements restrict adoption among smaller laboratories despite improving automation.

United States Multiomics Market Opportunities

AI-Guided Integrated Analysis Expands Translational Research Potential

AI-enabled platforms are reducing analytical fragmentation across 4 or more molecular modalities. Illumina incorporated feedback from 40 early-access users before the full 2026 release of Connected Multiomics and introduced AI-guided functionality within roughly 2 months of launch. Automated research systems have separately demonstrated generation of 360 hypotheses from 10 clinical multiomics datasets, creating opportunities for faster biomarker prioritization and therapeutic research.

Challenges in United States Multiomics Market

Data Harmonization and Cross-Platform Reproducibility Remain Critical

Integrating genomic, transcriptomic, proteomic, metabolomic and epigenomic datasets requires alignment across 5+ fundamentally different measurement structures. Single-cell studies further introduce thousands to millions of cellular observations, while standardized metabolomics platforms can measure more than 1,000 compounds across 40+ classes. Consequently, normalization, batch correction, interoperability and reproducibility remain major technical challenges even as AI-supported workflows reduce manual analysis.

United States Multiomics Market Segmentation

The market is segmented by Omics Type, Application, Technology, Offering, and End User. Among quantified categories, genomics accounts for approximately 33.79% of 2026 omics revenue, while drug discovery and development accounts for approximately 28.61% of application revenue.

By Omics Type

Genomics is the largest omics category, increasing from USD 333.38 million in 2025 to USD 386.89 million in 2026 and USD 1,272.76 million by 2034 at a 16.05% CAGR. Its 2026 contribution is approximately 33.79%, reflecting extensive sequencing use in disease research, therapeutic development, and molecular profiling.

Transcriptomics is the fastest-growing quantified omics category at a 16.63% CAGR, rising from USD 241.94 million in 2026 to USD 828.29 million in 2034. Proteomics follows at USD 173.33 million in 2026 and USD 584.53 million by 2034 with a 16.41% CAGR.

By Application

Drug Discovery and Development leads applications at USD 327.17 million in 2026 and is forecast to reach USD 1,072.59 million by 2034 at a 16.00% CAGR. It contributes approximately 28.61% of the 2026 application total.

Nutrigenomics records the fastest application CAGR at 16.58%, reaching USD 338.65 million by 2034 from USD 99.26 million in 2026. Clinical diagnostics grows at 16.46%, while infectious disease surveillance advances at 16.37%.

By Technology

Technology segmentation comprises next-generation sequencing, mass spectrometry, microarrays, single-cell analysis, real-time PCR, and multiomics integration platforms. Numerical technology-level revenue was not supplied; consequently, no unsupported market values or CAGR percentages are assigned.

By Offering

Offerings comprise software and services, instruments, and consumables. The 2026 total addressable market is USD 1,145.11 million by the primary omics dataset, but offering-level allocation percentages were not provided and are therefore not estimated.

By End User

End users include pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations, hospitals and clinics, and government and public health agencies. Application data indicate USD 327.17 million associated with drug discovery and development in 2026, although direct end-user allocation cannot be calculated from the supplied dataset.

United States Multiomics Market Outlook

The United States market reaches USD 1,145.11 million in 2026 and USD 3,807.66 million by 2034. California and major East Coast biotechnology clusters are important centers for sequencing, spatial biology, pharmaceutical R&D and computational biology; however, the supplied mandatory dataset contains no state- or county-level revenue allocation. Therefore, percentage regional shares and production values are not fabricated.

Nationally, genomics contributes approximately 33.79% of quantified 2026 omics revenue, transcriptomics approximately 21.13% and proteomics approximately 15.14%. These figures represent the supplied United States sector split rather than individual state or county contributions.

Top players in United States Multiomics Market

1. Illumina, Inc.
2. Thermo Fisher Scientific Inc.
3. Bruker Corporation
4. 10x Genomics, Inc.
5. Agilent Technologies, Inc.
6. QIAGEN N.V.
7. Bio-Rad Laboratories, Inc.
8. Pacific Biosciences
9. Standard BioTools Inc.
10. Waters Corporation
11. SCIEX
12. Becton, Dickinson and Company
13. Oxford Nanopore Technologies
14. Parse Biosciences
15. Element Biosciences

Top Two Companies

• Illumina, Inc.

A validated company-specific percentage share was not supplied and is therefore not assigned. The company strengthened its positioning through Connected Multiomics, launched in 2026 after engagement with 40 early-access users. The platform integrates at least 4 major molecular layers and received AI-assisted capabilities in v1.1 during February 2026, followed by expanded eQTL and pQTL workflows in June. This positions Illumina across sequencing, single-cell workflows, analytics and cloud-based interpretation rather than solely instrument supply.

• Bruker Corporation

A reliable company-level percentage share is likewise not available from the supplied dataset. Bruker expanded its integrated portfolio through its 2025 acquisition of biocrates, adding metabolomics kits, assays, software and services capable of covering 1,000+ metabolites and 40+ metabolite classes. Its broader portfolio also incorporates proteomics and spatial biology assets, strengthening competitive positioning across mass spectrometry, metabolomics, lipidomics and spatial multiomics.

Recent Developments in United States Multiomics Market

• 2026: Illumina moved Connected Multiomics into full customer release, integrating multiple molecular data types within one cloud environment.
• 2026: Illumina introduced v1.1 with AI-assisted workflow suggestions for multiomic exploration.
• 2026: Connected Multiomics v1.2 added end-to-end eQTL and pQTL workflows and deeper analytical integration.
• 2025: Bruker acquired biocrates, expanding capabilities across 1,000+ metabolites and more than 40 metabolite classes.
• 2025: Illumina unveiled roadmap technologies spanning genomics, spatial transcriptomics, single-cell analysis, CRISPR, epigenetics and multimodal analytics.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 treated as historical years. Mandatory supplied numerical tables are the primary basis for market values, segment contribution and CAGR calculations. The principal dataset moves from USD 985.45 million in 2025 to USD 1,145.11 million in 2026 and USD 3,807.66 million in 2034 at a 16.11% CAGR. External primary-company and research sources are used only for technology, competitive and development context; unavailable state, county, technology, offering, end-user and company-share percentages are not fabricated.